Cancer 'Invisibility Cloak' Shattered by New Drug

Researchers have developed an experimental drug, GRWD5769, designed to unmask cancer cells that hide from the immune system, thereby enhancing the effectiveness of immunotherapy treatments. Early trial results presented at a major oncology conference indicated that this 'smart drug' helped shrink tumours by at least 30% in six common cancer types.

The trial, conducted in the UK, France, Spain, and Australia, involved 83 patients with cervical, bladder, liver, bowel, lung, or head and neck cancers. These participants had previously exhausted treatment options with little success. The drug works by inhibiting the ERAP1 enzyme, effectively removing the "invisibility cloak" that cancer cells use to evade T-cells.

GRWD5769 demonstrated the ability to shrink tumours across all six cancer types studied. Significant tumour reductions were observed, and the drug also halted disease progression for at least six months in a notable percentage of patients, particularly those with bowel and lung cancers. These promising early findings suggest GRWD5769 could significantly improve immunotherapy's performance.

Developed by Oxford-based Greywolf Therapeutics, the drug is administered as a tablet and was well-tolerated by patients. While further studies are planned, the initial results offer genuine optimism for a new therapeutic approach with a novel mechanism and few side effects, potentially transforming outcomes for many hard-to-treat cancers.